Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Public ClinicalTrials.gov record NCT04887870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Study identification
- NCT ID
- NCT04887870
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- Enfortumab Vedotin-Ejfv Drug
- Ipilimumab Drug
- Nivolumab Drug
- Pembrolizumab Drug
- Sitravatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2021
- Primary completion
- Apr 20, 2025
- Completion
- Sep 24, 2025
- Last update posted
- Oct 9, 2025
2021 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers - Littleton | Littleton | Colorado | 80218 | — |
| Local Institution - 516-014-029 | Goshen | Indiana | 46526 | — |
| Local Institution - 516-014-002 | Boston | Massachusetts | 02215 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Local Institution - 516-014-005 | Minneapolis | Minnesota | 55455 | — |
| Urology Cancer Center and GU Research Network | Omaha | Nebraska | 68130 | — |
| Local Institution - 516-014-011 | Albany | New York | 12208 | — |
| Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building | New York | New York | 10065 | — |
| Local Institution - 516-014-004 | Columbus | Ohio | 43210 | — |
| Local Institution - 516-014-001 | Austin | Texas | 78758 | — |
| USOR - Texas Oncology Northeast Texas - Denison | Denison | Texas | 75020 | — |
| Local Institution - 516-014-013 | Houston | Texas | 77030 | — |
| NEXT Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04887870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04887870 live on ClinicalTrials.gov.